Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Teicoplanin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  Next»
    Study title: Pharmacokinetics of teicoplanin in children. - Tarral E, Jehl F, Tarral A et al. (1988) - Journal of Antimicrobial Chematherapy 21, Supplement A, 47-51.
    Active substance: TEICOPLANIN
    Study summary document link (including results):
    View full study record
    Document reference: 44306
    Study title: Report in Clinical documentation for Marketing Authorisation Application (June 1987): Clinical study of the efficacy and safety of teicoplanin in the treatment of Gram-positive infections - Schiraldi O., Terragna A., De Rosa F., Olivero S. - 4 March 1987Report in Clinical documentation for Marketing Authorisation Application (June 1987): Clinical study of the efficacy and safety of teicoplanin in the treatment of Gram-positive infections - Schiraldi O., Terragna A., De Rosa F., Olivero S. - 4 March 1987
    Active substance: TEICOPLANIN
    Study summary document link (including results):
    View full study record
    Document reference: 44316
    Study title: Report in Clinical documentation for Marketing Authorisation Application (June 1987): Drug experience reports on 2 children receiving overdosage of teicoplaninReport in Clinical documentation for Marketing Authorisation Application (June 1987): Drug experience reports on 2 children receiving overdosage of teicoplanin
    Active substance: TEICOPLANIN
    Study summary document link (including results):
    View full study record
    Document reference: 44317
    Study title: Report in Clinical documentation for Marketing Authorisation Application (June 1987): Efficacy and tolerability of teicoplanin in infections caused by Gram-positive organisms - Del Favero A. - 28 November 1985Report in Clinical documentation for Marketing Authorisation Application (June 1987): Efficacy and tolerability of teicoplanin in infections caused by Gram-positive organisms - Del Favero A. - 28 November 1985
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY Gram positive - Del Favero.xls
    View full study record
    Document reference: 44318
    Study title: Report in Clinical documentation for Marketing Authorisation Application (June 1987): Evaluation of therapeutic efficacy and tolerability of teicoplanin in serious infections caused by Gram-positive micro-organisms - Martino - 28 November 1985Report in Clinical documentation for Marketing Authorisation Application (June 1987): Evaluation of therapeutic efficacy and tolerability of teicoplanin in serious infections caused by Gram-positive micro-organisms - Martino - 28 November 1985
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY Serious infections - Martino.xls
    View full study record
    Document reference: 44320
    Study title: Report in Clinical documentation for Marketing Authorisation Application (March 1987): European Multicentre open study of teicoplanin in Gram-positive infection ; 1987 sponsor summary - P.J. Lewis - 6 April 1987
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY EG-87-42.xls
    View full study record
    Document reference: 44310
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): Clinical Pharmacology of teicoplanin in children - Milner R.D.G., Whincup G. - 1985Report in Clinical documentation for Marketing Autorisation Application (June 1987): Clinical Pharmacology of teicoplanin in children - Milner R.D.G., Whincup G. - 1985
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY pharmacological.xls
    View full study record
    Document reference: 44315
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): Clinical study of the efficacy and safety of teicoplanin in the treatment of Gram-positive infections - Concia E., Andreoni M., Suter F. - 4 March 1987
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY DRC 357.DLI.1075.xls
    View full study record
    Document reference: 44296
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): Clinical study of the efficacy and safety of teicoplanin in the treatment of Gram-positive infections - Dietrich H.A., Fell J.J., Pugnetti P. - 6 February 1987
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY LP-SM-0025.xls
    View full study record
    Document reference: 44297
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): Clinical study of the efficacy and safety of teicoplanin in the treatment of Gram-positive infections - Schiraldi O., Terragna A., De Rosa F., Olivero S. - 4 March 1987
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY DRC 356.DLI.1074.xls
    View full study record
    Document reference: 44298
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): Efficacy and safety of teicoplanin in the treatment of infections caused by Gram-positive cocci. A summary report of over 298 cases treated in France - Garaud J.J., Tarra -17/02/1987
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY EG-87.03.xls
    View full study record
    Document reference: 44299
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): Efficacy and tolerability of teicoplanin in infections caused by Gram-positive organisms - Martinetto P. - 22 November 1985Report in Clinical documentation for Marketing Autorisation Application (June 1987): Efficacy and tolerability of teicoplanin in infections caused by Gram-positive organisms - Martinetto P. - 22 November 1985
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY Gram positive - Martinetto.xls
    View full study record
    Document reference: 44319
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): European Multicentre open study of teicoplanin in Gram-positive infection ; 1987 sponsor summary - P.J. Lewis - 6 April 1987
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY EG-87-42.xls
    View full study record
    Document reference: 44300
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): Evaluation of therapeutic efficacy and tolerability of teicoplanin in serious infections caused by Gram-positive micro-organisms - Terragna A. - 28 November 1985Report in Clinical documentation for Marketing Autorisation Application (June 1987): Evaluation of therapeutic efficacy and tolerability of teicoplanin in serious infections caused by Gram-positive micro-organisms - Terragna A. - 28 November 1985
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY Serious infections - Terragna.xls
    View full study record
    Document reference: 44321
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): Pharmacokinetics of teicoplanin in paediatric patients - Rosina R., Bernareggi A., Danese A., Cavenaghi L - 14 November 1986
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY DRC 348.DLI 1039.xls
    View full study record
    Document reference: 44301
    Study title: Report in Clinical documentation for Marketing Autorisation Application (June 1987): Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients - Garaud J.J. - 9 March 1987
    Active substance: TEICOPLANIN
    Study summary document link (including results): Teicoplanin STUDY EG-87-16.xls
    View full study record
    Document reference: 44302
    Study title: Summary - Clinical documentation for Marketing Autorisation Application - June 1987Summary - Clinical documentation for Marketing Autorisation Application - June 1987
    Active substance: TEICOPLANIN
    Study summary document link (including results):
    View full study record
    Document reference: 44322
    Study title: Summary of clinical studies of the efficacy and safety of teicoplanin in the treatment of Gram-positive infections in the UK and Eire- Concia E., Andreoni M., Suter F. - 4 March 1987 ; Report in Clinical documentation for Marketing Autorisation Application - June 1987
    Active substance: TEICOPLANIN
    Study summary document link (including results):
    View full study record
    Document reference: 44303
    Study title: Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients. - Lemerle S, De la Roque F, Lamy R, et al. - J Antimicrob Chemother 1988; 21, S.A.: 112-116.Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients. - Lemerle S, De la Roque F, Lamy R, et al. - J Antimicrob Chemother 1988; 21, S.A.: 112-116.
    Active substance: TEICOPLANIN
    Study summary document link (including results):
    View full study record
    Document reference: 44324
    Study title: Teicoplanin in gram-positive paediatric infections. (Abstract) In: Abstracts of the 8th mediterranean congress of chemotherapy. - Careddi P, Boccazzi A, Mosconi G. - Athens, 24-29 May 1992: 236.Teicoplanin in gram-positive paediatric infections. (Abstract) In: Abstracts of the 8th mediterranean congress of chemotherapy. - Careddi P, Boccazzi A, Mosconi G. - Athens, 24-29 May 1992: 236.
    Active substance: TEICOPLANIN
    Study summary document link (including results):
    View full study record
    Document reference: 44325
    1  2  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 19 08:32:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA